HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DoJ Enlists Supporting Cast Against ‘Bad Actors’ On Supplement Stage

This article was originally published in The Tan Sheet

Executive Summary

DoJ explores broader action and new avenues to rid the supplement market of noncompliant firms, Deputy Assistant Attorney General Olin says at a FDLI conference. CFSAN Deputy Director Michael Roosevelt says identification of unknown supplement ingredients is a 2016 priority.

You may also be interested in...



Tracking Federal Agencies’ Enforcement In Supplement Space

““The Tan Sheet” provides links to previous articles on many of the enforcements DoJ announced from its year-long sweep.

DoJ Aims To ‘Do Something About’ Crime In FDA-Regulated Industries

In a frank warning at a FDLI meeting, DoJ Director of Consumer Protection Michael Blume says the agency’s role is clear once it takes on a case investigated by FDA or FTC. Blume notes the dietary supplement category “has become something of an emphasis for us in the department.”

U.S. Military Investigates Supplement Ingredient DMAA, Bans Sales

DoD suspends DMAA sales at military stores after regulators in Canada and New Zealand restricted access and as some U.S. firms change how they market and label the ingredient. These moves and the potential for an FDA review could lead to enforcement against DMAA similar to the 2004 ban against ephedra’s use in supplements.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS123544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel